Table 1 Checklist of items to include when reporting a study developing or validating a multivariable prediction model for diagnosis or prognosisa

From: Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): The TRIPOD statement

Section/topic

Item

Development or validation?

Checklist item

Page

Title and abstract

Title

1

D;V

Identify the study as developing and/or validating a multivariable prediction model, the target population, and the outcome to be predicted.

 

Abstract

2

D;V

Provide a summary of objectives, study design, setting, participants, sample size, predictors, outcome, statistical analysis, results, and conclusions.

 

Introduction

Background and objectives

3a

D;V

Explain the medical context (including whether diagnostic or prognostic) and rationale for developing or validating the multivariable prediction model, including references to existing models.

 
 

3b

D;V

Specify the objectives, including whether the study describes the development or validation of the model, or both.

 

Methods

Source of data

4a

D;V

Describe the study design or source of data (e.g., randomised trial, cohort, or registry data), separately for the development and validation data sets, if applicable.

 
 

4b

D;V

Specify the key study dates, including start of accrual; end of accrual; and, if applicable, end of follow-up.

 

Participants

5a

D;V

Specify key elements of the study setting (e.g., primary care, secondary care, general population) including number and ___location of centres.

 
 

5b

D;V

Describe eligibility criteria for participants.

 
 

5c

D;V

Give details of treatments received, if relevant.

 

Outcome

6a

D;V

Clearly define the outcome that is predicted by the prediction model, including how and when assessed.

 
 

6b

D;V

Report any actions to blind assessment of the outcome to be predicted.

 

Predictors

7a

D;V

Clearly define all predictors used in developing the multivariable prediction model, including how and when they were measured.

 
 

7b

D;V

Report any actions to blind assessment of predictors for the outcome and other predictors.

 

Sample size

8

D;V

Explain how the study size was arrived at.

 

Missing data

9

D;V

Describe how missing data were handled (e.g., complete-case analysis, single imputation, multiple imputation) with details of any imputation method.

 

Statistical analysis methods

10a

D

Describe how predictors were handled in the analyses.

 
 

10b

D

Specify type of model, all model-building procedures (including any predictor selection), and method for internal validation.

 
 

10c

V

For validation, describe how the predictions were calculated.

 
 

10d

D;V

Specify all measures used to assess model performance and, if relevant, to compare multiple models.

 
 

10e

V

Describe any model updating (e.g., recalibration) arising from the validation, if done.

 

Risk groups

11

D;V

Provide details on how risk groups were created, if done.

 

Development vs validation

12

V

For validation, identify any differences from the development data in setting, eligibility criteria, outcome, and predictors.

 

Results

Participants

13a

D;V

Describe the flow of participants through the study, including the number of participants with and without the outcome and, if applicable, a summary of the follow-up time. A diagram may be helpful.

 
 

13b

D;V

Describe the characteristics of the participants (basic demographics, clinical features, available predictors), including the number of participants with missing data for predictors and outcome.

 
 

13c

V

For validation, show a comparison with the development data of the distribution of important variables (demographics, predictors, and outcome).

 

Model development

14a

D

Specify the number of participants and outcome events in each analysis.

 
 

14b

D

If done, report the unadjusted association between each candidate predictor and outcome.

 

Model specification

15a

D

Present the full prediction model to allow predictions for individuals (i.e., all regression coefficients, and model intercept or baseline survival at a given time point).

 
 

15b

D

Explain how to use the prediction model.

 

Model performance

16

D;V

Report performance measures (with CIs) for the prediction model.

 

Model updating

17

V

If done, report the results from any model updating (i.e., model specification, model performance).

 

Discussion

Limitations

18

D;V

Discuss any limitations of the study (such as nonrepresentative sample, few events per predictor, missing data).

 

Interpretation

19a

V

For validation, discuss the results with reference to performance in the development data, and any other validation data.

 
 

19b

D;V

Give an overall interpretation of the results, considering objectives, limitations, results from similar studies, and other relevant evidence.

 

Implications

20

D;V

Discuss the potential clinical use of the model and implications for future research

 

Other information

Supplementary information

21

D;V

Provide information about the availability of supplementary resources, such as study protocol, Web calculator, and data sets.

 

Funding

22

D;V

Give the source of funding and the role of the funders for the present study.

 
  1. aItems relevant only to the development of a prediction model are denoted by D, items relating solely to a validation of a prediction model are denoted by V, and items relating to both are denoted D;V. We recommend using the TRIPOD Checklist in conjunction with the TRIPOD explanation and elaboration document.